medinfoАктуальные проблемы теоретической и клинической медициныActual Problems of Theoretical and Clinical Medicine2790-12892790-1297Казахстанско-Российский медицинский университет10.24412/2790-1289-2021-13840medinfo-80Research ArticleОБЗОР ЛИТЕРАТУРЫREVEWSПОРАЖЕНИЕ ПЕЧЕНИ ПРИ СOVID-19LIVER INJURY IN COVID - 19ПолукчиТ. В.PolukchiT. V.АбуоваГ. Н.AbuovaG. N.https://orcid.org/0000-0001-6335-6125СлавкоЕ. А.SlavkoE. A.

к.м.н., доцент

Candidate of Medical Sciences, Associate Professor

СарыпбековаЛ. Л.SarypbekovaL. L.https://orcid.org/0000-0002-5695-5290КасымоваТ. В.KasymovaT. V.«Южно-Казахстанская медицинская академия»КазахстанSouth Kazakhstan Medical AcademyKazakhstanАО «Казахский медицинский университет непрерывного образования»КазахстанKazakh Medical university of сontinuing educationKazakhstan202121102022013840Copyright © Полукчи Т.В., Абуова Г.Н., Славко Е.А., Сарыпбекова Л.Л., Касымова Т.В., 20222022Полукчи Т.В., Абуова Г.Н., Славко Е.А., Сарыпбекова Л.Л., Касымова Т.В.Polukchi T.V., Abuova G.N., Slavko E.A., Sarypbekova L.L., Kasymova T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://kazrosmedjournal.krmu.edu.kz/jour/article/view/80

В декабре 2019 года в городе Ухань, Китай была впервые зарегистрирована вспышка ранее неизвестной пневмонии, вызванная новым коронавирусом SARS-CoV-2. В настоящее время COVID-19 рассматривается как системное заболевание с поражением различных органов, в том числе и печени. Однако механизм повреждения печени при COVID-19 является недостаточно изученным. Отмечается высокая летальность пациентов с поражением печени и сопутствующим COVID-19, что указывает на неблагоприятный исход заболевания.

An outbreak of previously unknown pneumonia caused by the novel coronavirus SARS-CoV-2 was first reported in Wuhan, China in December 2019. Currently, COVID-19 is considered a systemic disease with damage to various organs including the liver. However, the mechanism of liver damage in COVID - 19 is not well understood. There is a high mortality rate in patients with liver damage and concomitant COVID-19 which indicates an unfavorable outcome of the disease

заболеваниевызванное новым коронавирусомпоражение печенихронические вирусные гепатитыцирроз печенипеченочная недостаточностьdisease caused by a novel coronavirusliver damagechronic viral hepatitisliver cirrhosisliver failureReferencesClinical characteristics of coronavirus disease 2019 in China. Guan W.J., Ni Z.Y., Hu Y., et al. N Engl J Med. 2020; 382:1708–1720.Clinical characteristics of coronavirus disease 2019 in China. Guan W.J., Ni Z.Y., Hu Y., et al. N Engl J Med. 2020; 382:1708–1720.Jotwani R., Cheung C.A., Hoyler M.M. Trial under fire: one New York City anaesthesiology residency programme's redesign for the COVID-19 surge. Br J Anaesth. 2020;125:e386–e388.Jotwani R., Cheung C.A., Hoyler M.M. Trial under fire: one New York City anaesthesiology residency programme's redesign for the COVID-19 surge. Br J Anaesth. 2020;125:e386–e388.Сандлер Ю.Г., Винницкая Е.В., Хайменова Т.Ю., Бордин Д.С. Клинические аспекты повреждения печени при COVID-19 // Эффективная фармакотерапия - Том 16- №15- С.18-23.Сандлер Ю.Г., Винницкая Е.В., Хайменова Т.Ю., Бордин Д.С. Клинические аспекты повреждения печени при COVID-19 // Эффективная фармакотерапия - Том 16- №15- С.18-23.Xu L., Liu J., Lu M. et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020; 40 (5):998-1004. doi: 10.1111/liv.14435.Xu L., Liu J., Lu M. et al. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020; 40 (5):998-1004. doi: 10.1111/liv.14435.Chai X., Hu L., Zhang Y., et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020; 2020 (02):03.931766.Chai X., Hu L., Zhang Y., et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. bioRxiv. 2020; 2020 (02):03.931766.Melquist S., Estepp K., Aleksandrovich Y., Lee A., Beiseker A., Hamedani F.S., Bassett J. COVID-19 presenting as fulminant hepatic failure: A case report. Medicine (Baltimore). 2020 Oct 23; 99 (43):e22818. doi: 10.1097/ MD.0000000000022818.Melquist S., Estepp K., Aleksandrovich Y., Lee A., Beiseker A., Hamedani F.S., Bassett J. COVID-19 presenting as fulminant hepatic failure: A case report. Medicine (Baltimore). 2020 Oct 23; 99 (43):e22818. doi: 10.1097/ MD.0000000000022818.Alqahtani S.A., Schattenberg J.M. Liver injury in COVID - 19: The current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-519. doi: 10.1177/2050640620924157. PMID: 32450787; PMCID: PMC7268949.Alqahtani S.A., Schattenberg J.M. Liver injury in COVID - 19: The current evidence. United European Gastroenterol J. 2020 Jun;8(5):509-519. doi: 10.1177/2050640620924157. PMID: 32450787; PMCID: PMC7268949.Ильченко Л.Ю., Никитин И.Г., Федоров И.Г. COVID-19 и поражение печени // Архивъ внутренней медицины-2020.-Том 10-№ 3 (53) - С. 188-197.Ильченко Л.Ю., Никитин И.Г., Федоров И.Г. COVID-19 и поражение печени // Архивъ внутренней медицины-2020.-Том 10-№ 3 (53) - С. 188-197.Wu J., Song S., Cao H.C., Li L.J. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J. Gastroenterol. 2020 May 21; 26 (19): 2286-2293. doi: 10.3748/wjg.v26.i19.2286.Wu J., Song S., Cao H.C., Li L.J. Liver diseases in COVID-19: Etiology, treatment and prognosis. World J. Gastroenterol. 2020 May 21; 26 (19): 2286-2293. doi: 10.3748/wjg.v26.i19.2286.Kumar R., Semaine W., Johar M., Tyrrell D.L., Agrawal B. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl) ethoxy) methyl] moiety, able to mimic natural 2 - deoxyribose, on wild-type and mutant hepatitis B virus replication. J Med Chem. 2006; 49: 3693–3700.Kumar R., Semaine W., Johar M., Tyrrell D.L., Agrawal B. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl) ethoxy) methyl] moiety, able to mimic natural 2 - deoxyribose, on wild-type and mutant hepatitis B virus replication. J Med Chem. 2006; 49: 3693–3700.Zha L., Li S., Pan L., Tefsen B., Li Y., French N., Chen L., Yang G., Villanueva E.V. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Med J Aust. 2020.Zha L., Li S., Pan L., Tefsen B., Li Y., French N., Chen L., Yang G., Villanueva E.V. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19) Med J Aust. 2020.Aghayari Sheikh Neshin S., Basirjafari S., Saberi A., Shahhosseini B., Zarei M. Liver abnormality may develop cerebral vein thrombosis in COVID-19. J Neurol Sci. 2020 Oct 15;417:117076. doi: 10.1016/j.jns.2020.117076. Epub 2020 Aug 5.Aghayari Sheikh Neshin S., Basirjafari S., Saberi A., Shahhosseini B., Zarei M. Liver abnormality may develop cerebral vein thrombosis in COVID-19. J Neurol Sci. 2020 Oct 15;417:117076. doi: 10.1016/j.jns.2020.117076. Epub 2020 Aug 5.Melquist S., Estepp K., Aleksandrovich Y., Lee A., Beiseker A., Hamedani F.S., Bassett J. COVID-19 presenting as fulminant hepatic failure: A case report. Medicine (Baltimore). 2020 Oct 23;99 (43): e22818. doi: 10.1097/ MD.0000000000022818.Melquist S., Estepp K., Aleksandrovich Y., Lee A., Beiseker A., Hamedani F.S., Bassett J. COVID-19 presenting as fulminant hepatic failure: A case report. Medicine (Baltimore). 2020 Oct 23;99 (43): e22818. doi: 10.1097/ MD.0000000000022818.Makarem J., Naghibi N., Beigmohammadi M.T., Foroumandi M., Mehrpooya M.A. Case Report of Progressive Liver Failure Inappropriate to Decompensated Heart Failure Following Infection with COVID-19. Cureus. 2020 Aug 30;12(8): e10142. doi: 10.7759 / cureus.10142.Makarem J., Naghibi N., Beigmohammadi M.T., Foroumandi M., Mehrpooya M.A. Case Report of Progressive Liver Failure Inappropriate to Decompensated Heart Failure Following Infection with COVID-19. Cureus. 2020 Aug 30;12(8): e10142. doi: 10.7759 / cureus.10142.Shalimar, Elhence A., Vaishnav M., Kumar R., Pathak P., Soni K.D., Aggarwal R., Soneja M., Jorwal P., Kumar A., Khanna P., Singh A.K., Biswas A., Nischal N., Dar L., Choudhary A., Rangarajan K., Mohan A., Acharya P., Nayak B., Gunjan D., Saraya A., Mahapatra S., Makharia G., Trikha A., Garg P. Poor outcomes in patients with cirrhosis and Corona Virus Disease-19. Indian J. Gastroenterol. 2020 Jun; 39(3):285-291. doi: 10.1007/s12664-020-01074-3. Epub 2020 Aug 15.Shalimar, Elhence A., Vaishnav M., Kumar R., Pathak P., Soni K.D., Aggarwal R., Soneja M., Jorwal P., Kumar A., Khanna P., Singh A.K., Biswas A., Nischal N., Dar L., Choudhary A., Rangarajan K., Mohan A., Acharya P., Nayak B., Gunjan D., Saraya A., Mahapatra S., Makharia G., Trikha A., Garg P. Poor outcomes in patients with cirrhosis and Corona Virus Disease-19. Indian J. Gastroenterol. 2020 Jun; 39(3):285-291. doi: 10.1007/s12664-020-01074-3. Epub 2020 Aug 15.Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Tai Y., Bai C., Gao T., Song J., Xia P., Dong J., Zhao J., Wang F.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420 - 422.Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., Tai Y., Bai C., Gao T., Song J., Xia P., Dong J., Zhao J., Wang F.S. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420 - 422.

The authors declare that there are no conflicts of interest present.